Submission of Un Audited Financial Results along with Limited Review Report for the quarter ended on 30.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Hemo Organic Limited reported its unaudited financial results for Q1 FY26 (ended 30 June 2025). Revenue from operations collapsed to just Rs. 0.19 lakh, compared to Rs. 241.43 lakh in the same quarter last year — a near-total wipeout. Total income for the quarter stood at Rs. 0.38 lakh against total expenses of Rs. 11.64 lakh, leading to a pre-tax loss of Rs. 11.45 lakh and a net loss of Rs. 8.57 lakh (vs a profit of Rs. 16.39 lakh in Q1 FY25). Loss per share was Rs. 0.25. The statutory auditor (MAAK & Associates) issued a qualified review report, flagging that no balance confirmations or supporting details were available for trade receivables and trade payables, making those balances unverifiable.
Sharp negative for shareholders: revenue has virtually disappeared, the company has swung to a quarterly loss, and the auditor's qualification on receivables/payables adds credibility and governance concerns. Watch for any clarification on the reasons for the revenue collapse and management's plan to restore operations.